
CytoSorbents (CTSO) Stock Forecast & Price Target
CytoSorbents (CTSO) Analyst Ratings
Bulls say
CytoSorbents Corp demonstrated a robust financial performance with a reported revenue of $9.5 million, reflecting a 10% year-over-year growth and a gross margin exceeding 70%, attributed to improved geographic mix and manufacturing efficiencies. The company showcased significant advancements in distributor-driven revenue, with sales from global distribution partners growing 14.4% year-over-year, highlighting strong execution in international markets that supports the potential for future growth. Additionally, ongoing efforts to enhance the product pipeline, particularly DrugSorb-ATR, along with the anticipation of returning to growth in the German market by 2026, underscore a promising outlook for continued operational improvement and financial stability.
Bears say
CytoSorbents Corp has revised its revenue projections downward for both 2025 and 2026, reflecting a decline from $39.8 million to $38.2 million and from $46.3 million to $40.8 million, respectively. The company continues to experience stagnant commercial sales in Germany, which significantly impacts its overall revenue growth, given that this market is critical to its financial performance. Consequently, the adjusted price target for the stock has been reduced from $1.00 to $0.75 per share, further indicating concerns over the company's financial trajectory and performance outlook.
This aggregate rating is based on analysts' research of CytoSorbents and is not a guaranteed prediction by Public.com or investment advice.
CytoSorbents (CTSO) Analyst Forecast & Price Prediction
Start investing in CytoSorbents (CTSO)
Order type
Buy in
Order amount
Est. shares
0 shares